News & Events

November 20, 2011

Forbes Announces IntegriChain in Top 20 List of America’s Most Promising Companies

INTEGRICHAIN IS NAMED #19 ON FORBES’ 2011 LIST OF AMERICA’S MOST PROMISING COMPANIES

Princeton, NJ – November 30, 2011 – IntegriChain, Inc., a commercial insight provider supporting the pharmaceutical industry, was identified by Forbes as #19 on the list of America’s Most Promising Companies. IntegriChain offers 3-5 year subscription based services to help customers improve order forecasting, order monitoring, better manage their sales and marketing activities, and production planning. IntegriChain has grown 60% over the past three years and plans on continuing to do so over the next 3-4, achieving 70-75% of the market share on data coverage across all of US life sciences.

“We are truly in some rarified air on this list,” said IntegriChain CEO Kevin Leininger. “I am thrilled that we have been selected.” Leininger was sponsored by Forbes to participate the Aileron Course for Presidents where he participated in a 30-minute interview with founder Clay Mathile, the video of which can be found on Forbes.com.

Forbes‘ list of America’s Most Promising Companies features 100 privately held up-and-comers with compelling business models, strong management teams, notable customers, strategic partners and precious investment capital.

“Sizing up younger, privately held companies is hard: Their fortunes can change very quickly and there’s a dearth of public data,” says Forbes Executive Editor Brett Nelson. “We took a more comprehensive approach to evaluate their health and potential.”

To sharpen its search, Forbes teamed up with CB Insights, a Manhattan-based data firm that tracks investment in high-growth private companies. With $650,000 in grants from the National Science Foundation, CB has developed complex software called Mosaic that mines myriad online sources (from press releases and social networks to job boards and court filings) to come up with one, algorithmically derived score that measures a private company’s health. Forbes married Mosaic’s data-crunching with old-fashioned reporting to assemble a list of rising stars with bright growth prospects. To view the complete the list, please visit www.forbes.com/ampc.

About IntegriChain
IntegriChain, Inc. launched the Demand Network Analytics (DNA) commerce platform in 2007. Today, DNA is helping a growing community of innovative manufacturers realize their vision of a truly demand driven enterprise. DNA’s trade data management and analytic applications optimize hundreds of billions of dollars in annual commerce, helping manufacturers lower their distribution costs, improve sales predictability, and ensure product availability throughout their distribution channels. For more information, please visit www.integrichain.com.

All names referred to are trademarks or registered trademarks of their respecitve owners.

adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71 icon-distribution-distribution-contract-management icon-distribution-distribution-data-refinery icon-distribution-inventory-analytics icon-distribution-retail-analytics icon-patient-patient-data-refinery icon-patient-patient-services-analytics icon-patient-specialty-pharmacy-analytics icon-payer-340b-analytics icon-payer-analytics icon-payer-g2n icon-payer-government-pricing icon-payer-rebate-management Asset 1 hand hand hand hand hand hand hand hand hand hand hand